Pfizer Cuts Recifercept for Achondroplasia Program
Pfizer punts pair of orphan drugs amid rare disease R&D rethink Pfizer, amid a rethink of its rare disease R&D strategy, has punted (PDF) a pair of orphan drug candidates from its…
Therachon
Pfizer Acquires Clinical-Stage Biotech Therachon
Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today…
Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia
BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today announced the dosing of the first subject in its Phase 1 trial for TA-46,…
Therachon Receives EMA and FDA Orphan Drug Designation for TA-46 for Achondroplasia
BASEL, Switzerland — June 20, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today that the European Medicines Agency (EMA) and the U.S. Food and Drug…